Related Experiment Videos
HLA-identical sibling peripheral blood progenitor cell transplants (PBPCT)
1TransOnc Consulting, Arlington, VA, USA.
Bone Marrow Transplantation
|October 12, 1999
Summary
Peripheral blood progenitor cell (PBPC) transplants offer an alternative to traditional stem cell sources. This review highlights key factors for successful PBPC transplantation, including cell dose thresholds for engraftment and graft-versus-host disease prevention.
Area of Science:
- Hematology
- Transplantation Immunology
- Cellular Therapy
Background:
- Peripheral blood progenitor cells (PBPC) are increasingly explored as an alternative stem cell source for allogeneic transplantation.
- Establishing evidence-based guidelines is crucial for optimizing PBPC transplantation protocols.
Purpose of the Study:
- To present a state-of-the-art review of HLA-identical sibling peripheral blood progenitor cell transplantation (PBPCT).
- To identify critical cell dose thresholds and prognostic factors influencing transplant outcomes.
Main Methods:
- Systematic review of Medline search results and transplant center meeting reports.
- Analysis of data to determine threshold CD34+ cell numbers for engraftment.
- Evaluation of CD3+ cell numbers in relation to acute and chronic graft-versus-host disease (GVHD).
Main Results:
- Identified threshold CD34+ cell numbers essential for rapid engraftment.
- Determined threshold CD3+ cell numbers for preventing acute GVHD.
- Found evidence suggesting infused CD3+ cell dose influences chronic GVHD, a significant concern in allogeneic PBPCT.
Conclusions:
- Systematic reviews are valuable for planning future clinical research in allogeneic PBPCT.
- Optimizing cell dose is critical for mitigating GVHD and improving patient outcomes in PBPC transplantation.